Should I Buy BDMD? BDMD 2026 Analysis

Should You Buy Baird Medical Investment Holdings Ltd (BDMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.920

1 Day change

1.77%

52 Week Range

7.260

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the broader trend remains bearish (SMA_200 > SMA_20 > SMA_5) and the pattern-based forecast points to downside over the next month (-16.11%).
The pre-market +3% move to ~1.03 looks like a small bounce near support, not a confirmed trend reversal.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
With no proprietary “strong buy” signals and weak fundamentals (no revenue, ongoing losses), the risk/reward is unfavorable for an impatient buyer looking for immediate follow-through.

Technical Analysis

Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating sustained downtrend.
Momentum: MACD histogram is negative (-0.00909) but contracting, suggesting selling pressure may be easing (early stabilization), not a confirmed reversal.
RSI: RSI_6 at ~29.6 (near oversold). This can support a short-term bounce, but oversold conditions alone are not a buy signal in a downtrend.
Key levels: Price ~1.03 is just above S1 (1.003) and below pivot (1.071). A failure to reclaim/hold above ~1.071 keeps the setup weak; upside levels are R1 1.14 then R2 1.182.
Similar-pattern stats: modest near-term upside potential (next day +0.06%, next week +2.14%) but materially negative next month (-16.11%), aligning with the bearish trend.

Positive Catalysts

- News sentiment: Mildly positive operational headline (training/masterclass in Shanghai) that can support visibility/adoption, but it is not a clear near-term financial catalyst.
- Technical: Near-oversold RSI and pre-market bounce may extend into a short-lived relief rally if support holds.

Neutral/Negative Catalysts

- Downtrend remains intact (bearish MA stack) and pattern-based outlook signals significant 1-month downside risk (-16.11%).
- No Intellectia buy signals today (neither AI Stock Picker nor SwingMax), reducing confidence in an immediate tactical entry.
- Trading trends: Hedge funds neutral; insiders neutral—no supportive “smart money” accumulation signal.
- Congress trading: No recent data available (no positive confirmation from influential buyer activity).

Financial Performance

Latest provided quarter: 2024/Q2.
Revenue: 0 (no YoY growth indicated), implying lack of operating scale/traction in reported results.
Profitability: Net income -858,731 and EPS -0.43 (still loss-making).
Margins: Gross margin reported at 82.11%, but with zero revenue this does not translate into demonstrated operating momentum.
Overall: Financial snapshot does not show improving growth trends; losses persist.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data provided, so there is no observable Wall Street upgrade/downgrade trend to support a buy case.
Wall Street pros/cons view (based only on available data):
- Pros: Potential product/physician adoption narrative from training activities.
- Cons: Lack of demonstrated revenue growth and ongoing losses; bearish technical trend; no strong tactical signals.

Analyst Rating

Wall Street analysts forecast BDMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDMD is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 0.905

Low

Averages

High